Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.
For patients with type 2 diabetes or cardiovascular disease, GLP-1 receptor agonists like liraglutide and semaglutide offer additional benefits beyond weight loss, including reduced cardiovascular risk and potential mitigation of atherosclerosis through anti-inflammatory effects.
StrongSupportsHIGH confidence
it has been proved that liraglutide and semaglutide can mitigating cardiovascular risks (Fig. 1) (Marso et al 2016; Wilding et al. 2021), and may mitigate atherosclerosis through anti-inflammatory mechanisms(Rakipovski et al 2018).
Why this rating
Cites major trials (Marso 2016, Wilding 2021) and mechanistic studies (Rakipovski 2018).
Source
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Yu-Fei Zhou et al. · Current Medicine · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →